At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing.
Mike Farkas, PhD
Advertisement
Mike Farkas, PhD, is an associate professor of ophthalmology at the University of Buffalo.
Articles by Mike Farkas, PhD
Advertisement
Latest Updated Articles
Envision Summit 2025: Beyond the status quo in gene therapyPublished: February 22nd 2025 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
AAO 2025: A practice’s experience with connecting "the why," building community for techs
3
Treating myopia today: US-focused treatments, challenges, and global insights
4
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
5
.png "Optometry Times"){kind=logo}
